GSK homepage Annual Report
Annual review Downloads

                               
       
        2000           1999           1998    
            Business performance       Business performance        
    Business performance Merger, restructuring
and disposal
of subsidiaries
Total   Restructuring
and disposal
of subsidiaries
Total   Restructuring
and disposal
of subsidiaries
Total    
Retained
businesses
Divested
business
Total Retained
businesses
Divested
business
Total
  Notes £m £m £m   £m £m £m £m £m   £m £m £m £m £m    
Turnover 7 18,079 - 18,079   16,164 632 16,796 - 16,796   14,938 1,064 16,002 - 16,002    
                                     
Cost of sales   (3,811) (151) (3,962)   (3,499) (436) (3,935) (399) (4,334)   (3,300) (622) (3,922) (46) (3,968)    
Gross profit   14,268 (151) 14,117   12,665 196 12,861 (399) 12,462   11,638 442 12,080 (46) 12,034    
Selling, general and administrative expenditure   (6,732) (404) (7,136)   (6,002) (170) (6,172) (74) (6,246)   (5,375) (365) (5,740) (136) (5,876)    
Research and development expenditure   (2,510) (16) (2,526)   (2,285) (1) (2,286) - (2,286)   (2,072) (1) (2,073) - (2,073)    
                                     
Trading profit   5,026 (571) 4,455   4,378 25 4,403 (473) 3,930   4,191 76 4,267 (182) 4,085    
Other operating income/(expense) 9 274 - 274   413 - 413 - 413   221 - 221 - 221    
Operating profit 8,10 5,300 (571) 4,729   4,791 25 4,816 (473) 4,343   4,412 76 4,488 (182) 4,306    
Share of profits/(losses) of joint ventures and associated undertakings 8,11 65 (8) 57   15 - 15 (8) 7   22 - 22 - 22    
Profit on disposal of interest in associate 32 144 - 144   39 - 39 - 39   - - - - -    
Profit on dissolution of joint venture   - - -   - - - - -   57 - 57 - 57    
Product divestments 8 - 1,416 1,416   - - - - -   - - - - -    
Merger transaction costs 8 - (121) (121)   - - - - -   - - - - -    
Disposal of businesses:                                    
Provision for loss on disposal   - - -   - - - - -   - - - (629) (629)    
Loss on disposal 8 - (14) (14)   - - - (635) (635)   - - - - -    
Utilisation of provision 8 - - -   - - - 644 644   - - - - -    
Profit before interest   5,509 702 6,211   4,845 25 4,870 (472) 4,398   4,491 76 4,567 (811) 3,756    
Net interest payable 12 (182) - (182)   (162) - (162) - (162)   (192) - (192) - (192)    
                                     
Profit on ordinary activities before taxation   5,327 702 6,029   4,683 25 4,708 (472) 4,236   4,299 76 4,375 (811) 3,564    
Taxation 8,13 (1,454) (245) (1,699)   (1,320) (7) (1,327) 109 (1,218)   (1,256) (20) (1,276) 299 (977)    
Profit on ordinary activities after taxation   3,873 457 4,330   3,363 18 3,381 (363) 3,018   3,043 56 3,099 (512) 2,587    
Minority interests   (120) - (120)   (110) - (110) - (110)   (102) - (102) - (102)    
Preference share dividends   (56) - (56)   (49) - (49) - (49)   (50) - (50) - (50)    
Earnings (Profit attributable to shareholders) 14 3,697 457 4,154   3,204 18 3,222 (363) 2,859   2,891 56 2,947 (512) 2,435    
                                     
Earnings per Ordinary Share 14 -   68.5 p     -   46.7 p     -   39.9 p  
Adjusted earnings per Ordinary Share 14 61.0
-       52.7 p -       48.3 p -    
Diluted earnings per Ordinary Share 14 -   67.7 p     -   46.3 p     -   39.4 p  
                                     
Profit attributable to shareholders       4,154           2,859           2,435    
Dividends 15     (2,097)           (2,005)           (1,903)    
Retained profit       2,057           854           532    
                                     
All items dealt with in arriving at operating profit relate to continuing activities. There is no difference between the profit on ordinary activities before taxation and the retained profit stated above and their historical cost equivalents.
 
                                     
                                     
 
  Back to top
  Updated March 22, 2001 - © 2001-2002 GlaxoSmithKline - All Rights Reserved
Legal Notices
- Privacy Statement